Aktuellt
SENASTE
Bactiguard’s Q2 sales of SEK 46m were in line with our expectations, however, excluding a milestone payment from Zimmer Biomet (SEK 8.5m) that we have included for H2/21, sales were weaker than we had expected. Q2 adj. EBITDA amounted to SEK 2m. Bactiguard comments that it saw a continued stabilisation of licence revenues from BD and it expects the roll-out of vaccines to gradually have a positive effect on the return to a normal situation for healthcare.
LÄS MER
